Why the study?
Does dabigatran reduce ischaemic stroke and major bleeding compared to warfarin in patients with non-valvular atrial fibrillation?
Does dabigatran reduce ischaemic stroke and major bleeding compared to warfarin in patients with non-valvular atrial fibrillation?
This editorial raises critical concerns about the safety, data transparency, and regulatory approval of dabigatran, challenging its unmonitored use in non-valvular atrial fibrillation.
QScience.com is the innovative and collaborative, peer-reviewed, online publishing platform from Hamad bin Khalifa University Press (HBKU Press). It offers a fast and transparent Open Access scholarly publishing process, which is centered on the author, bringing their research to a global audience.
No takes yet. Share an insight, caveat, or question.
Kaba et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: